These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19454394)

  • 1. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.
    Hirsch IB; Yuan H; Campaigne BN; Tan MH
    Endocr Pract; 2009; 15(4):343-8. PubMed ID: 19454394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
    Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
    Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
    Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
    Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
    Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal.
    Gross JL; Rojas A; Shah S; Tinahones FJ; Cleall S; Rodríguez A
    Curr Med Res Opin; 2016 Jun; 32(6):1109-16. PubMed ID: 26934128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
    Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
    Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.
    Sakharova OV; Lleva RR; Dziura JD; Spollett GR; Howell SK; Beisswenger PJ; Inzucchi SE
    J Diabetes Complications; 2012; 26(4):333-8. PubMed ID: 22541894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.
    Rosenstock J; Ahmann AJ; Colon G; Scism-Bacon J; Jiang H; Martin S
    Diabetes Care; 2008 Jan; 31(1):20-5. PubMed ID: 17934150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
    Koivisto V; Cleall S; Pontiroli AE; Giugliano D
    Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
    J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus.
    Jeong IK; Chung CH; Zhou Z; Han JH; Duan R; Edralin DM; Rodriguez A
    J Diabetes; 2017 Apr; 9(4):396-404. PubMed ID: 27171584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.